Literature DB >> 24853695

Rapid and cost effective screening of breast and ovarian cancer genes using novel sequence capture method in clinical samples.

Kristóf Arvai1, Péter Horváth, Bernadett Balla, Anna M Tőkés, Bálint Tobiás, István Takács, Zsolt Nagy, Péter Lakatos, János P Kósa.   

Abstract

BRCA1 and BRCA2 are two well-known genes in the background of hereditary breast and ovarian cancer. There is also evidence that several other genes play an important role in the pathogenesis of these two malignancies. Latest population-scaled studies showed that certain mutations in different genes could cause similar risk elevation like BRCA2 mutations. In this study we present a new method to analyse the risk assessment of women to breast and ovarian cancer. Using Haloplex, a novel sequence capture method combined with next-generation sequencing we were able to perform rapid and cost-effective screening of 16 genes that could be associated with an increased risk of breast and ovarian cancer. The rapid and cost effective analysis of this 16-gene cohort can reveal the genetic background of approximately 30 % of hereditary and familiar cases of breast and ovarian cancers. Thus, it opens up a new and high-throughput approach with fast turnaround time to the genetic diagnostics of these disorders and may be helpful to investigate other familial genetic disorders as well.

Entities:  

Mesh:

Year:  2014        PMID: 24853695     DOI: 10.1007/s10689-014-9730-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  26 in total

1.  Germline RAD51C mutations in ovarian cancer susceptibility.

Authors:  F Coulet; A Fajac; C Colas; M Eyries; A Dion-Minière; R Rouzier; S Uzan; J-P Lefranc; M Carbonnel; F Cornelis; A Cortez; F Soubrier
Journal:  Clin Genet       Date:  2012-07-23       Impact factor: 4.438

2.  Integrating next-generation sequencing into the diagnostic testing of inherited cancer predisposition.

Authors:  C S Ku; D N Cooper; B Iacopetta; D H Roukos
Journal:  Clin Genet       Date:  2012-10-29       Impact factor: 4.438

3.  Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.

Authors:  Tom Walsh; Ming K Lee; Silvia Casadei; Anne M Thornton; Sunday M Stray; Christopher Pennil; Alex S Nord; Jessica B Mandell; Elizabeth M Swisher; Mary-Claire King
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

4.  Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.

Authors:  M Van Der Looij; C Szabo; I Besznyak; G Liszka; B Csokay; T Pulay; J Toth; P Devilee; M C King; E Olah
Journal:  Int J Cancer       Date:  2000-06-01       Impact factor: 7.396

5.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration.

Authors:  Helga Thorvaldsdóttir; James T Robinson; Jill P Mesirov
Journal:  Brief Bioinform       Date:  2012-04-19       Impact factor: 11.622

6.  A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers.

Authors:  Michael A Quail; Miriam Smith; Paul Coupland; Thomas D Otto; Simon R Harris; Thomas R Connor; Anna Bertoni; Harold P Swerdlow; Yong Gu
Journal:  BMC Genomics       Date:  2012-07-24       Impact factor: 3.969

Review 7.  Technical and implementation issues in using next-generation sequencing of cancers in clinical practice.

Authors:  D Ulahannan; M B Kovac; P J Mulholland; J-B Cazier; I Tomlinson
Journal:  Br J Cancer       Date:  2013-07-25       Impact factor: 7.640

8.  The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  J Iqbal; A Ragone; J Lubinski; H T Lynch; P Moller; P Ghadirian; W D Foulkes; S Armel; A Eisen; S L Neuhausen; L Senter; C F Singer; P Ainsworth; C Kim-Sing; N Tung; E Friedman; M Llacuachaqui; S Ping; S A Narod
Journal:  Br J Cancer       Date:  2012-10-25       Impact factor: 7.640

9.  Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.

Authors:  Marc Tischkowitz; Nelly Sabbaghian; Nancy Hamel; Carly Pouchet; William D Foulkes; Anne-Marie Mes-Masson; Diane M Provencher; Patricia N Tonin
Journal:  BMC Med Genet       Date:  2013-01-09       Impact factor: 2.103

10.  PALB2 and breast cancer: ready for clinical translation!

Authors:  Melissa C Southey; Zhi L Teo; Ingrid Winship
Journal:  Appl Clin Genet       Date:  2013-07-19
View more
  1 in total

1.  A haplotype in CFH family genes confers high risk of rare glomerular nephropathies.

Authors:  Yin Ding; Weiwei Zhao; Tao Zhang; Hao Qiang; Jianping Lu; Xin Su; Shuzhen Wen; Feng Xu; Mingchao Zhang; Haitao Zhang; Caihong Zeng; Zhihong Liu; Huimei Chen
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.